Atara Biotherap
ATRA8.0910.38% ( +0.031 )
Atara Biotherap (ATRA)
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and inte...
- Open
- 8.180
- High
- 8.220
- Low
- 7.920
- Prev. Close
- 8.060
- Volume
- 6.39K
- Turnover
- 51.72K
- Avg Price
- 8.090
- Bid/Ask Ratio
- --
- Amplitude
- 3.72%
- 52wk High
- 19.145
- Volume Ratio
- 0.60
- Turnover Ratio
- 0.16%
Atara Biotherap Analyst Rating
View MoreForecast & Rating
Jun 18, 2026Price forecast
$13.6768.91%
Forecast & RatingBuy
4analysts
- Strong buy75.00%
- Buy0.00%
- Hold25.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · Jul 20 at 07:05 AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
- PUBT · Jul 6 at 03:15 PM
Atara Biotherapeutics files initial beneficial ownership statement for interim CFO Kevin Sarney
- PUBT · Jun 26 at 03:16 PM
Atara Biotherapeutics names Kevin Sarney interim CFO
- Tip Ranks · Jun 21 at 03:16 AM
Mizuho Securities Sticks to Their Buy Rating for Atara Biotherapeutics (ATRA)
- Tip Ranks · Jun 12 at 04:09 PM
Atara Biotherapeutics Adds Independent Director to Board
- prnewswire · May 26 at 08:01 AM
09:00 ETThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA
